Hailiang Education Group Inc. (HLG) Touches $69.84 High on Mar, 16; PROTEON THERAPEUTICS (PRTO)’s Sentiment Is 1.57

March 16, 2018 - By Matt Maslow

The stock of Hailiang Education Group Inc. (NASDAQ:HLG) reached all time high today, Mar, 16 and still has $76.13 target or 9.00% above today’s $69.84 share price. This indicates more upside for the $1.80 billion company. This technical setup was reported by Barchart.com. If the $76.13 PT is reached, the company will be worth $162.00 million more. The stock increased 1.79% or $1.23 during the last trading session, reaching $69.84. About 36,615 shares traded. Hailiang Education Group Inc. (NASDAQ:HLG) has risen 5.27% since March 16, 2017 and is uptrending. It has underperformed by 11.43% the S&P500.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $39.64 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

Deer Vii & Co. Ltd. holds 10.12% of its portfolio in Proteon Therapeutics, Inc. for 315,101 shares. Abingworth Llp owns 2.02 million shares or 2.72% of their US portfolio. Moreover, Mpm Asset Management Llc has 0.96% invested in the company for 983,381 shares. The Massachusetts-based Ra Capital Management Llc has invested 0.24% in the stock. Deerfield Management Co, a New York-based fund reported 1.22 million shares.

Since January 1, 0001, it had 1 insider buy, and 0 selling transactions for $22,560 activity.

Ratings analysis reveals 50% of Proteon Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating Proteon Therapeutics, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $3.0 while the high is $19.0. The stock’s average target of $10.75 is 377.78% above today’s ($2.25) share price. PRTO was included in 6 notes of analysts from September 22, 2016. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, December 14. Robert W. Baird downgraded the stock to “Neutral” rating in Tuesday, December 13 report. The firm has “Mkt Perform” rating by JMP Securities given on Wednesday, December 14. The stock of Proteon Therapeutics, Inc. (NASDAQ:PRTO) has “Strong Buy” rating given on Wednesday, October 26 by Raymond James. The firm has “Buy” rating given on Thursday, November 10 by Maxim Group. The firm has “Buy” rating by H.C. Wainwright given on Thursday, September 22.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.